{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:01:38Z","timestamp":1777914098699,"version":"3.51.4"},"reference-count":61,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Toxicol Pathol"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak that started in Wuhan, China, in 2019 resulted in a pandemic not seen for a century, and there is an urgent need to develop safe and efficacious vaccines. The scientific community has made tremendous efforts to understand the disease, and unparalleled efforts are ongoing to develop vaccines and treatments. Toxicologists and pathologists are involved in these efforts to test the efficacy and safety of vaccine candidates. Presently, there are several SARS-CoV-2 vaccines in clinical trials, and the pace of vaccine development has been highly accelerated to meet the urgent need. By 2021, efficacy and safety data from clinical trials are expected, and potentially a vaccine will be available for those most at risk. This review focuses on the ongoing SARS-CoV-2 vaccine development efforts with emphasis on the nonclinical safety assessment and discusses emerging preliminary data from nonclinical and clinical studies. It also provides a brief overview on vaccines for other coronaviruses, since experience gained from these can be useful in the development of SARS-CoV-2 vaccines. This review will also explain why, despite this unprecedented pace of vaccine development, rigorous standards are in place to ensure nonclinical and clinical safety and efficacy.<\/jats:p>\n                  <jats:p>[Box: see text]<\/jats:p>","DOI":"10.1177\/0192623320959090","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T16:01:41Z","timestamp":1600099301000},"page":"800-809","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":31,"title":["Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)"],"prefix":"10.1177","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1079-4505","authenticated-orcid":false,"given":"Bindu M.","family":"Bennet","sequence":"first","affiliation":[{"name":"Voyager Therapeutics, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayanthi","family":"Wolf","sequence":"additional","affiliation":[{"name":"Merck & Co, Inc, Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Laureano","sequence":"additional","affiliation":[{"name":"Moderna Inc, Cambridge, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8870-4675","authenticated-orcid":false,"given":"Rani S.","family":"Sellers","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Pearl River, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"issue":"4","key":"bibr1-0192623320959090","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/135965350701200S01.1","volume":"12","author":"Van Der Hoek L","year":"2007","journal-title":"Antivir Ther"},{"issue":"69","key":"bibr2-0192623320959090","first-page":"3","volume":"16","author":"Schoeman D","year":"2019","journal-title":"Virol J"},{"key":"bibr3-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.0757"},{"key":"bibr4-0192623320959090","doi-asserted-by":"publisher","DOI":"10.3390\/v4061011"},{"key":"bibr5-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1038\/nature12711"},{"key":"bibr6-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1809667116"},{"key":"bibr7-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02615-14"},{"key":"bibr8-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.81651-0"},{"key":"bibr9-0192623320959090","unstructured":"The New York Times Coronavirus Vaccine Tracker. Accessed September 08, 2020. https:\/\/www.nytimes.com\/interactive\/2020\/science\/coronavirus-vaccine-tracker.html"},{"key":"bibr10-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2005630"},{"key":"bibr11-0192623320959090","unstructured":"Expectations for a COVID-19 Vaccine. Assoc Press Opin Res Cent Poll, May 2020. Accessed September 08, 2020. https:\/\/apnorc.org\/projects\/expectations-for-a-covid-19-vaccine\/"},{"key":"bibr12-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-3527(08)60286-9"},{"key":"bibr13-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-2438-7_1"},{"key":"bibr14-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2004.08.008"},{"key":"bibr15-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1002\/path.1570"},{"key":"bibr16-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108427"},{"key":"bibr17-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2456-9"},{"key":"bibr18-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc4776"},{"issue":"13","key":"bibr19-0192623320959090","first-page":"093195","volume":"5","author":"Doremalen NV","year":"2020","journal-title":"Biorxiv"},{"key":"bibr20-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024671"},{"key":"bibr21-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0327-4"},{"key":"bibr22-0192623320959090","unstructured":"World Health Organization Transmission of SARS-CoV-2: implications for infection prevention precautions. Scientific brief dated July 09, 2020. Accessed September 08, 2020. https:\/\/www.who.int\/news-room\/commentaries\/detail\/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions"},{"key":"bibr23-0192623320959090","unstructured":"Symptoms of Coronavirus Disease 2019 (COVID-19). Updated May 13, 2020. Accessed September 08, 2020. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/symptoms-testing\/symptoms.html"},{"key":"bibr24-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05190-5"},{"key":"bibr25-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117900"},{"key":"bibr26-0192623320959090","unstructured":"Coronavirus Disease 2019 (COVID-19): People with Certain Medical Conditions. Updated August 14, 2020. Accessed September 08, 2020. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/people-with-medical-conditions.html"},{"key":"bibr27-0192623320959090","unstructured":"Coronavirus Disease 2019 (COVID-19): Older Adults. Updated August 16, 2020. Accessed September 08, 2020. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/older-adults.html"},{"key":"bibr28-0192623320959090","unstructured":"COVID-19 Information for pediatric healthcare providers. Center for Disease Prevention and Control. Updated August 19, 2020. Accessed September 08, 2020. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/pediatric-hcp.html"},{"key":"bibr29-0192623320959090","first-page":"69422","author":"Coronavirus Disease 2019 in Children\u2014 United States","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"bibr30-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2020.1948"},{"key":"bibr31-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcped.2020.05.010"},{"key":"bibr32-0192623320959090","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6932e3"},{"key":"bibr33-0192623320959090","author":"Tsabouri S","year":"2020","journal-title":"Pediatr Clin North Am"},{"key":"bibr34-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021680"},{"key":"bibr35-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.2014.3085"},{"key":"bibr36-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/100.2.111"},{"key":"bibr37-0192623320959090","unstructured":"European Medicines Agency. Note for guidance on preclinical pharmacological and toxicological testing of vaccines. Accessed September 08, 2020. https:\/\/www.ema.europa.eu\/en\/preclinical-pharmacological-toxicological-testing-vaccines"},{"key":"bibr38-0192623320959090","unstructured":"World Health Organization. Annex 2. Guidelines on the Nonclinical Evaluation of Vaccine Adjuvants and Adjuvanted Vaccines. World Health Organization, 2013. WHO Technical Report Series, TRS 987, Annex 2; 2020. Accessed September 08, 2020. https:\/\/www.who.int\/biologicals\/areas\/vaccines\/TRS_987_Annex2.pdf"},{"key":"bibr39-0192623320959090","unstructured":"European Medicines Agency. Guideline on adjuvants in vaccines for human use. 2005. Accessed September 08, 2020. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-adjuvants-vaccines-human-use-see-also-explanatory-note_en.pdf"},{"key":"bibr40-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1177\/0192623319875085"},{"key":"bibr41-0192623320959090","unstructured":"World Health Organization. Annex 1. Guidelines on the Nonclinical Evaluation of Vaccines. World Health Organization WHO Technical Report Series, No. 927; 2005. Accessed September 08, 2020. https:\/\/www.who.int\/biologicals\/publications\/trs\/areas\/vaccines\/nonclinical_evaluation\/ANNEX%201Nonclinical.P31-63.pdf"},{"key":"bibr42-0192623320959090","unstructured":"World Health Organization Guidelines on the quality, safety and efficacy of Ebola vaccines. 2020. Accessed September 08, 2020. https:\/\/www.who.int\/biologicals\/areas\/vaccines\/Annex_2_WHO_TRS_1011_web-2.pdf"},{"key":"bibr43-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-0204-7"},{"key":"bibr44-0192623320959090","unstructured":"United States Food and Drug Administration Center for Biologics evaluation and Research. Development and licensure of vaccines to prevent COVID-19: guidance for industry. 2020. Accessed September 08, 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/development-and-licensure-vaccines-prevent-covid-19"},{"key":"bibr45-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.05.064"},{"key":"bibr46-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.06.005"},{"key":"bibr47-0192623320959090","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.02991"},{"key":"bibr48-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00220-10"},{"key":"bibr49-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a120955"},{"key":"bibr50-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020781"},{"key":"bibr51-0192623320959090","first-page":"NEJMoa2022483","author":"Jackson LA","year":"2020","journal-title":"N Engl J Med"},{"key":"bibr52-0192623320959090","author":"Sahin U","year":"2020","journal-title":"Med Rxiv"},{"key":"bibr53-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2607-z"},{"key":"bibr54-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.06.026"},{"key":"bibr55-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/424860"},{"issue":"4","key":"bibr56-0192623320959090","first-page":"278","volume":"66","author":"Takamura K","year":"2002","journal-title":"Can J Vet Res"},{"key":"bibr57-0192623320959090","doi-asserted-by":"publisher","DOI":"10.3390\/v6083363"},{"key":"bibr58-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2014.04.017"},{"key":"bibr59-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X13500429"},{"key":"bibr60-0192623320959090","author":"Zhang L","year":"2020","journal-title":"Biorxiv Prepr Serv Biol"},{"key":"bibr61-0192623320959090","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.06.043"}],"container-title":["Toxicologic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0192623320959090","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0192623320959090","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0192623320959090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:41:19Z","timestamp":1777653679000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0192623320959090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,14]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1177\/0192623320959090"],"URL":"https:\/\/doi.org\/10.1177\/0192623320959090","relation":{},"ISSN":["0192-6233","1533-1601"],"issn-type":[{"value":"0192-6233","type":"print"},{"value":"1533-1601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,14]]}}}